ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Global Diversification
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Market Insights
    • Megatrends
    • Modern Alpha
    • Multi-Asset
    • Night Effect
    • Portfolio Strategies
    • Retirement Income
    • Richard Bernstein Advisors
    • Tax Efficient Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Index Education
    • Index Insights
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Multimedia
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • Company
    • About Us
    • Swag Store
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. ETF Building Blocks Channel
  2. SBIO ALPS’ Top Performing ETF in August
ETF Building Blocks Channel
Share

SBIO ALPS’ Top Performing ETF in August

Elle CarusoSep 01, 2022
2022-09-01

The ALPS Medical Breakthroughs ETF (SBIO B-) was ALPS’ top-performing ETF in August, propelled by positive earnings and M&A announcements in the portfolio.  

SBIO increased 8.65% on a total return basis between August 1 and August 31. During the same period, the SPDR S&P Biotech ETF (XBI A) increased by 5.32%, and the iShares Biotechnology ETF (IBB A-) decreased by 0.66%, according to YCharts.

SBIo Chart Graph Image

U.S. equities began August continuing in rebound mode but reversed course to end the month in negative territory after a hawkish Fed and recession fears weighed on investors. The S&P 500 posted a loss of 4%, while the S&P MidCap 400 and S&P SmallCap 600 performed similarly with 3% and 4% declines, according to recent S&P Dow Jones Indices commentary. 

SBIO’s small-to-mid cap holdings were beaten down in the first half of the year but, as history suggests, depressed valuations in the space ignited a wave of M&A in early August, leading SBIO to outperform its competitors and broader equities markets, ALPS wrote in an August insight.

SBIO’s early August rally was led by the news of immunotherapy company, ChemoCentryx Inc. (CCXI, 1.79% weight as of August 5), surging 113.89% after Amgen Inc. (AMGN, not in SBIO) announced it would acquire the company for $3.7 billion, or a 115% premium to its prior day close, according to ALPS

Global Blood Therapeutics Inc. (GBT, 2.07% weight as of August 5) also propelled mid-cap biotech last month on reports that the company, which produces a recently-approved immunotherapy for sickle-cell disease, may be acquired by Pfizer Inc. (PFE, not in SBIO) for an estimated $5 billion, or a 118% premium to its prior day close, ALPS wrote.

SBIO screens for small- to mid-cap biotech companies with at least one drug or therapy in Phase II or Phase III (late-stage) clinical trials. According to ALPS, late-stage drug trials can potentially capture greater odds of success as they are further along the Food & Drug Administration’s drug trial process.

Constituents in SBIO must have at least 24 months of cash burn on hand, which helps protect against the equity dilution that comes with raising capital to support drug trials, according to ALPS. SBIO’s underlying index, the S-Network Medical Breakthroughs Index (PMBI), has a weighted average cash burn of 38 months that continues to exceed peer biotechnology indexes and is a distinguishing defensive characteristic for the fund.

For more news, information, and strategy, visit the ETF Building Blocks Channel.

vettafi.com is owned by VettaFi, which also owns the index provider for SBIO. VettaFi is not the sponsor of SBIO, but VettaFi’s affiliate receives an index licensing fee from the ETF sponsor.


Content continues below advertisement

Loading Articles...
Help & Info
  • Contact Us
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © 2023 VettaFi LLC. All rights reserved.
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X